Add office photos
Employer?
Claim Account for FREE
Glenmark Pharmaceuticals
3.9
based on 2.9k Reviews
Company Overview
Company Locations
Working at Glenmark Pharmaceuticals
Company Summary
0
Overall Rating
3.9/5
based on 2.9k reviews
On-Par with
industry average
Critically rated for
Promotions
Work Policy
Work from office
77% employees reported
Monday to Saturday
61% employees reported
Flexible timing
63% employees reported
Within city
36% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
223 employees reported
Health insurance
199 employees reported
Office cab/shuttle
155 employees reported
Cafeteria
56 employees reported
View all benefits
About Glenmark Pharmaceuticals
Founded in1977 (48 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersMumbai, Maharashtra, India
Office Locations
--
Websiteglenmarkpharma.com
Primary Industry
Other Industries
--
Are you managing Glenmark Pharmaceuticals's employer brand? To edit company information,
claim this page for free
Glenmark is a leading global innovative pharmaceutical company committed to enriching lives worldwide. Our vision is to discover possibilities and make lives of patients better across the globe by developing cures for unmet medical needs. We have a rich pipeline of innovative molecules in various phases of development which are targeted in areas of oncology, respiratory and dermatology.
Managing your company's employer brand?
Claim this Company Page for FREE
Glenmark Pharmaceuticals Ratings
based on 2.9k reviews
Overall Rating
3.9/5
How AmbitionBox ratings work?
5
1.3k
4
780
3
390
2
144
1
205
Category Ratings
3.7
Job security
3.7
Salary
3.7
Skill development
3.6
Company culture
3.6
Work-life balance
3.5
Work satisfaction
3.3
Promotions
Glenmark Pharmaceuticals is rated 3.9 out of 5 stars on AmbitionBox, based on 2.9k company reviews.This rating reflects an average employee experience, indicating moderate satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Glenmark Pharmaceuticals
based on 2.7k reviews
3.9
Rated by 210 Women
Rated 3.8 for Job security and 3.8 for Skill development
3.9
Rated by 2.5k Men
Rated 3.7 for Salary and 3.7 for Skill development
Work Policy at Glenmark Pharmaceuticals
based on 376 reviews in last 6 months
Work from office
77%
Hybrid
17%
Permanent work from home
6%
Glenmark Pharmaceuticals Reviews
Top mentions in Glenmark Pharmaceuticals Reviews
+ 5 more
Compare Glenmark Pharmaceuticals with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 3.9/5 based on 2.9k reviews | 4.0/5 based on 5.8k reviews | 4.1/5 based on 6.9k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | No highly rated category | Salary Skill development Job security | Skill development Salary Work-life balance | Skill development Work-life balance Salary |
Critically Rated for | Promotions | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 77% employees reported | Work from office 82% employees reported | Work from office 73% employees reported | - |
Rating by Women Employees | 3.9 Good rated by 210 women | 4.0 Good rated by 437 women | 4.1 Good rated by 682 women | - no rating available |
Rating by Men Employees | 3.9 Good rated by 2.5k men | 4.0 Good rated by 5k men | 4.1 Good rated by 5.8k men | - no rating available |
Job security | 3.7 Good | 3.8 Good | 3.7 Good | 4.0 Good |
View more
Glenmark Pharmaceuticals Salaries
Glenmark Pharmaceuticals salaries have received with an average score of 3.7 out of 5 by 2.9k employees.
Senior Officer
(946 salaries)
Unlock
₹1.9 L/yr - ₹8.8 L/yr
Officer
(837 salaries)
Unlock
₹1.1 L/yr - ₹6.5 L/yr
Junior Officer
(316 salaries)
Unlock
₹2 L/yr - ₹5.9 L/yr
Research Officer
(306 salaries)
Unlock
₹4.2 L/yr - ₹10.8 L/yr
Research Associate
(271 salaries)
Unlock
₹2.2 L/yr - ₹7.5 L/yr
District Sales Manager
(250 salaries)
Unlock
₹4.2 L/yr - ₹10.4 L/yr
Production Officer
(247 salaries)
Unlock
₹1.8 L/yr - ₹5.6 L/yr
Field Sales Officer
(239 salaries)
Unlock
₹2.8 L/yr - ₹6.5 L/yr
Medical Representative
(202 salaries)
Unlock
₹2 L/yr - ₹5.8 L/yr
Senior Research Officer
(172 salaries)
Unlock
₹7.5 L/yr - ₹16.2 L/yr
Glenmark Pharmaceuticals Interview Questions
Interview questions by designation
Top Glenmark Pharmaceuticals interview questions and answers
Get interview-ready with top interview questions
Glenmark Pharmaceuticals Jobs
Popular Skills Glenmark Pharmaceuticals Hires for
Current Openings
Glenmark Pharmaceuticals News
View all
Nifty Pharma Recovers As Dr. Reddy's, Glenmark Pharma Share Prices Lead
- Nifty Pharma erased losses despite weakness across most sectors of the market.
- The market-cap of pharmaceutical companies increased Rs 3,281.70 crore to Rs 15.83 lakh crore.
- Flight to safety is also one of the reasons behind the recovery of Nifty Pharma on Monday.
- Glenmark Pharmaceuticals settled the lawsuits related to generic drug Zeita and Vytorin against its US subsidiary.
Bloomberg Quint | 24 Feb, 2025
Glenmark Pharma Q3 Results Review— Regulatory Compliance Critical For Turnaround In U.S. Says ICICI Securities
- Glenmark Pharmaceuticals' Q3 FY25 result was dragged by weak show in India, US, and RoW markets.
- Revival in the US hinges on its ability to adhere with regulatory standards and timely approval of gFlovent and other assets.
- India biz revenue run-rate slowed down in Q3 FY25 and Glenmark's management now anticipates sales from India to grow at 9-10%.
- The brokerage maintains 'Reduce' on Glenmark Pharma with a lower target price of Rs 1,265, based on 22x FY26E EPS.
Bloomberg Quint | 18 Feb, 2025
Stock Market Highlights 17 February 2025: Sensex, Nifty crawl up to close marginally higher
- Sensex is getting support near 75,400 with resistance around 77,100. Nifty Bank index's immediate outlook is unclear, finding support near 48,700. Long-term supports include Nifty 50 at 22,500-22,000, Sensex at 74,000-72,000, and Nifty Bank at 48,000-46,600.
- Stock markets rebounded with Sensex closing higher by 57 points, driven by value buying in blue-chip stocks. Indian rupee depreciated against the US dollar due to foreign fund outflows and global uncertainty impacting the forex market.
- Eurobank partners with LTIMindtree to establish a Global Delivery Centre in Pune, enhancing banking operations and IT services. Various stocks like KIOCL Limited and Shakti Pumps (India) witnessed fluctuations in trading on the NSE.
- Arrow Capital, regulated by the Dubai Financial Services Authority (DFSA), has expanded its services globally. InCred acquires Arrow Capital, broadening its financial solutions globally.
- Quality Power Electrical Equipments' IPO saw 62% subscription on day 1, with Ajax Engineering IPO listing at a slight discount. Glenmark Pharma Chairman discussed US tariffs and upcoming launches.
- Financial highlights for various companies, such as Swan Energy, Kitex Garments, and UFLEX, with their net profits and revenues compared year-over-year.
- Earnings data for Q3FY25 & 9MFY25 showed growth in pre-provision operating profit and profit after tax, indicating resilience in the lending sector.
- Q3FY25 results for BSE500 and Nifty companies were modest, with slight improvement sequentially. Earnings downgrades continued, albeit at a slower pace, impacting valuations.
- Institutional flows remained resilient despite market corrections. Macroeconomic events like Federal Reserve meeting minutes and China loan rates are expected to influence market focus in the upcoming week.
- Nifty 50 closed with a loss of 2.68%, while Nifty Bank maintained a 2.11% loss. Weekly fund-flow activities showcased FIIs selling equities and DIIs buying in the cash segment.
HinduBusinessLine | 17 Feb, 2025
Glenmark’s US plant to gain amid geopolitical shifts, says CMD
- Glenmark's US plant expected to benefit from geopolitical shifts.
- Cipla and Piramal Pharma also highlight the advantages of having facilities in the US.
- Glenmark optimistic about US market with upcoming product launches.
- In India, Glenmark plans to launch more GLP-1 products for diabetes treatment.
HinduBusinessLine | 17 Feb, 2025
Glenmark Pharma Share Price Rises After India Sales Grow 300% In Q3
- Glenmark Pharmaceutical Ltd.'s shares rose over 5% during trade on Monday, after the management highlighted a 300.2% sales growth in India in the third quarter.
- The company's revenue rose 35% to Rs 3,388 crore, but missed Bloomberg analysts' estimate of Rs 3,489 crore.
- Glenmark Pharma reported a net profit of Rs 348 crore in the third quarter, compared to a loss of Rs 470 crore in the same period last year.
- The company plans to launch various drugs in the coming years and expects an uptick in business from financial year 2026.
Bloomberg Quint | 17 Feb, 2025
Stock Market Today: All You Need To Know Going Into Trade On Feb. 17
- The Indian equity benchmark indices closed lower on Friday, recording their longest losing streak in two years.
- Foreign portfolio investors continued as net sellers of Indian equities, while domestic institutional investors remained net buyers on Friday.
- The Indian rupee strengthened by six paise, closing at 86.83 against the US Dollar on Friday.
- Earnings highlights after market hours include companies like Northern Arc Capital, Glenmark Pharma, Cupid, Swan Energy, Easy Trip Planners, and more.
- Stocks to watch include JSW Energy, Zydus Lifesciences, Vodafone Idea, Alembic Pharmaceuticals, and Bharat Heavy Electricals, among others.
- In the IPO space, Hexaware Technologies saw good subscription on day three, while Quality Power Electrical Equipments saw lower subscription on day one.
- Insider trading activities were noted in companies like Nahar Spinning Mills, Kilburn Engineering, Paisalo Digital, and Alembic Pharmaceuticals.
- Trading tweaks included price band changes, ex-dividend dates, and stocks moving in and out of the short-term ASM framework.
- In F&O cues, Nifty Feb futures saw downward movement, and securities in the ban period included Deepak Nitrite.
- The Indian rupee strengthened further against the US Dollar at market open on Friday, reflecting positive market sentiment and possible support from the RBI.
Bloomberg Quint | 17 Feb, 2025
Glenmark Pharma clocks Q3 PAT of ₹348 crore
- Glenmark Pharmaceuticals reported a profit after tax (PAT) of ₹348 crore for the quarter ended December 31, 2024.
- The European and branded markets showed growth while the Indian and North American markets also performed well.
- Sales in India saw a 300% growth, while North America registered a 1.4% growth.
- Glenmark Pharmaceuticals submitted marketing applications in more than 90 countries for Ryaltris, with plans for launches in additional markets; clinical trials for Envafolimab are underway.
HinduBusinessLine | 15 Feb, 2025
Movers & Shakers: Stocks that will see action this week
- Glenmark Pharmaceuticals stock is showing signs of a potential uptrend, with a target of ₹1,800 in the near-term.
- Nippon Life India Asset Management stock remains in a downtrend, with potential resistance levels at ₹640 and ₹700.
- SRF stock recently experienced a breakout, indicating a potential rally after moderating to ₹2,500.
- SRF stock can be bought at ₹2,880, with a target of ₹4,000 and stop-loss levels at ₹2,000 and ₹3,600.
HinduBusinessLine | 8 Feb, 2025
Aurobindo Pharma, Glenmark, Zydus Recall Products In US
- Drug makers Aurobindo Pharma, Glenmark, and Zydus are recalling products in the US market due to manufacturing issues.
- Aurobindo Pharma USA Inc. is recalling over 1 lakh bottles of Cinacalcet tablets due to the presence of N-nitroso Cinacalcet impurity above FDA recommended limit.
- Glenmark Pharmaceuticals Inc, USA is recalling around 90,000 bottles of Diltiazem Hydrochloride extended-release capsules due to the presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended limit.
- Zydus Pharmaceuticals (USA) Inc is recalling 4,404 packs of Esomeprazole Magnesium for Delayed-Release Oral Suspension due to a labeling error.
Bloomberg Quint | 15 Dec, 2024
Aurobindo Pharma, Glenmark recall products in US
- Aurobindo Pharma USA Inc, Glenmark Pharmaceuticals Inc, USA, and Zydus Pharmaceuticals (USA) Inc are recalling products in the US market due to manufacturing issues.
- Aurobindo Pharma is recalling over 1 lakh bottles of Cinacalcet tablets due to the presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit.
- Glenmark Pharmaceuticals is recalling around 90,000 bottles of Diltiazem Hydrochloride extended-release capsules due to the presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.
- Zydus Pharmaceuticals is recalling 4,404 packs of Esomeprazole Magnesium for Delayed-Release Oral Suspension due to a labelling error.
Yourstory | 15 Dec, 2024
Powered by
Compare Glenmark Pharmaceuticals with
Biocon Limited
3.9
Zydus Lifesciences
4.1
Torrent Pharmaceuticals
3.9
Lupin
4.2
Aurobindo Pharma
4.0
DIVI'S Laboratories
3.7
Piramal Group
3.9
Dr. Reddy's
4.0
Intas Pharmaceuticals
4.1
Hetero
3.9
Viatris
4.2
Abbott
4.1
Alembic Pharmaceuticals
4.0
Alkem Laboratories
3.9
Ipca Laboratories
3.9
MSN Laboratories
3.7
Ajanta Pharma
4.1
Akums Drugs & Pharmaceuticals Limited
4.4
Cadila Pharmaceuticals
3.5
GlaxoSmithKline Pharmaceuticals
4.1
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to Glenmark Pharmaceuticals
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 5.8k reviews
Cipla
Manufacturing, Pharma
4.1
• 6.9k reviews
DRJ & CO
Architecture & Interior Design
5.0
• 1 reviews
Biocon Limited
Biotech & Life sciences, Biotechnology
3.9
• 1.9k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.1
• 6k reviews
Torrent Pharmaceuticals
Pharma
3.9
• 2.5k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.2
• 6k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.7k reviews
DIVI'S Laboratories
Pharma
3.7
• 1.4k reviews
Piramal Group
Pharma
3.9
• 1.1k reviews
Dr. Reddy's
Clinical Research, Pharma
4.0
• 6.8k reviews
Intas Pharmaceuticals
Biotech & Life sciences, Pharma
4.1
• 3.4k reviews
Glenmark Pharmaceuticals FAQs
When was Glenmark Pharmaceuticals founded?
Glenmark Pharmaceuticals was founded in 1977. The company has been operating for 48 years primarily in the Pharma sector.
Where is the Glenmark Pharmaceuticals headquarters located?
Glenmark Pharmaceuticals is headquartered in Mumbai, Maharashtra.
How many employees does Glenmark Pharmaceuticals have in India?
Glenmark Pharmaceuticals currently has more than 12,000+ employees in India. Marketing & Communication department appears to have the highest employee count in Glenmark Pharmaceuticals based on the number of reviews submitted on AmbitionBox.
Does Glenmark Pharmaceuticals have good work-life balance?
Glenmark Pharmaceuticals has a Work-Life Balance Rating of 3.6 out of 5 based on 2,800+ employee reviews on AmbitionBox. 74% employees rated Glenmark Pharmaceuticals 4 or above, while 26% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Glenmark Pharmaceuticals work-life balance reviews for more details
Is Glenmark Pharmaceuticals good for career growth?
Career growth at Glenmark Pharmaceuticals is rated as moderate, with a promotions and appraisal rating of 3.3. 26% employees rated Glenmark Pharmaceuticals 3 or below, while 74% employees rated it 4 or above on promotions/appraisal. This rating suggests that while some employees view growth opportunities favorably, there is scope for improvement based on employee feedback. We recommend reading Glenmark Pharmaceuticals promotions/appraisals reviews for more detailed insights.
What are the cons of working in Glenmark Pharmaceuticals?
Working at Glenmark Pharmaceuticals does have some drawbacks that potential employees should consider. The company is poorly rated for promotions / appraisal, based on 2,800+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
70 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
